John M Suffredini (@john_suffredini) profile picture

Interventional Cardiologist at @BCMHouston.

Houston, TX
Joined September 2020
John M Suffredini retweeted
BRIGHT 4 1-year now publ in Circ CV Interv. In 6016 STEMI pts PCI w/bivalirudin vs heparin→↓death, major bleed, stent thrombosis at 30d persisting to 1 yr. Results support the class I recommendation for use of bival to reduce mortality and bleeding in the latest US guidelines.
12
44
4,343
John M Suffredini retweeted
Our work from PREVENT now publ in Circ. Only 37% of FFR neg severe lsns (PB>70% & MLA<4mm2) were lipid-rich plaques (LRP) by NIRS. Event rates were much higher and preventive PCI was only effective in LRPs. PCI of "true vulnerable plaques" may improve prognosis and avoid over-Rx.
6
55
2
152
16,788
John M Suffredini retweeted
A Correction! Or, Why I Inflate The Stent Balloon 3 Times I typed in a rush. Intrinsic acute stent recoil is related to a particular property of any metal, that stretching it once does not deform it fully. In fact, it takes multiple ‘pulls’ to break the bonds between sheets of metal atoms/molecule, and cause them to take on a new configuration. 🤔 This is called ratcheting. There are elegant curves showing this. See below. Other fun terms we never get to use, but apply to stents include: cycle creep, plastic deformation, and structural failure. 😂 @DrJayMohan @SripalBangalore @aspergian1 @jedicath @stefan_harb @TWilsonMD @Hragy @DocSavageTJU
Replying to @DrJayMohan
Even before I started using the double/triple tap technique, I would keep the balloon up at supra nominal pressure for 20-30 sec. I was taught this by a senior colleague who had learnt it from Barry Uretsky. Of course, those stents were much bulkier. Turns out acute stent recoil is real, and related to the metal properties of the stent. The technical term for this is “ratcheting”.
7
22
66
10,956
John M Suffredini retweeted
Original Article: Aspirin Omission at the Time of Primary Percutaneous Coronary Intervention in STEMI (PREMIUM trial) nej.md/4gqcspb #ESCCongress | @escardio
1
21
3
89
33,954
John M Suffredini retweeted
Presented today and published in NEJM, our PADN-HF-PH trial in which 264 pts with left-heart failure (HFrEF or HFpEF) and pulmonary hypertension (mPAP >20 mmHg and PCWP >15 mmHg) were randomized at 25 centers to pulmonary artery denervation (PADN) + GDMT vs GDMT alone.
4
51
2
173
23,551
Prasugrel versus Ticagrelor in Acute Coronary Syndromes: @NEJM #ESCCongress2026 #ESCCongress 🥸 So many good trials - and STAREE is coming - SWITCH-SWEDEHEART 😱 Effient vs Brilinta in ACS - take a look 👇👇👇👇
2
54
1
225
23,716
John M Suffredini retweeted
🚨 The 2026 @escardio #HeartFailure Guidelines are here❗️#ESCcongress @secardiologia 1) HFmrEF is gone. Acute HF is gone. NT-proBNP cut-offs are now age-adjusted. Everything that matters 🧵👇 2/ 🔄 NEW DEFINITION — two phenotypes only ❤️‍🩹 HFrEF → LVEF <50% + symptoms/signs 🫀 HFpEF → LVEF ≥50% + symptoms/signs + objective evidence of structural/functional abnormality ❌ HFmrEF eliminated: same aetiology, same pathophysiology, same treatment response as HFrEF
7
250
10
568
42,910
John M Suffredini retweeted
The Fifth Universal Definition of Myocardial Infarction is out at ESC Congress 2026. Types 1-5 are gone. MI is now primary, secondary or procedure-related - classified by the pathophysiology behind it rather than by a number.
5
28
1
70
9,719
John M Suffredini retweeted
In the randomized KISS trial of non-LM bifurcations, a conservative strategy without systematic side branch (SB) intervention was noninferior to a systematic SB intervention regarding periprocedural myocardial infarction & myocardial injury. jacc.org/doi/10.1016/j.jcin.… #JACCINT #cvMI
1
34
2
93
11,478
John M Suffredini retweeted
Finally, a sham-controlled CTO PCI trial—and it delivers. ORBITA-CTO: small (n=50), but rigor where it matters—blinding, placebo control, symptom-level data. CTO PCI improves angina beyond placebo, with a clear reduction in episodes and more angina-free days. Not prognosis, not hard endpoints, but real symptom benefit—properly measured. #acc26 jacc.org/doi/10.1016/j.jacc.…
6
108
10
319
34,923
John M Suffredini retweeted
Presented at #ACC26: Among patients with atherosclerotic cardiovascular disease, targeting an LDL cholesterol level below 55 mg per deciliter led to a lower 3-year risk of cardiovascular events than targeting a level below 70 mg per deciliter. Full Ez-PAVE trial results: nejm.org/doi/full/10.1056/NE… Editorial: Paving the Road toward Targeted Lipid Lowering nejm.org/doi/full/10.1056/NE… @ACCinTouch
13
274
38
751
186,171
John M Suffredini retweeted
In diabetic patients with LM & TVD, #PCI was associated with ⬆️3yr risk for death, non-fatal MI & stroke (17.0% vs 12.4%; HR: 1.91; 95% CI: 1.50-2.44; P < 0.001). However, risk for the primary outcome was comparable between IVI-guided PCI & #CABG. jacc.org/doi/10.1016/j.jcin.… #JACCINT
2
19
3
46
6,859
John M Suffredini retweeted
It's an honor to be entrusted by @NASA to conduct our fifth commercial human spaceflight mission onboard the @Space_Station. Axiom Space has sent 14 astronauts, representing 11 nations to the station in the past 4 years, with crews conducting 160+ research and 100+ outreach activities. We are #BuildingOpportunity for countries around the world to access microgravity for discovery and inspire others to #TranscendEarth. None of this would be possible without the trust of our customers, partners and the hard work of #TeamAxiom. Read more: axiom.space/release/ax5-awar…
15
90
7
504
37,383
John M Suffredini retweeted
Thrilled to welcome our newest fellows to the BCM Cardiovascular Disease Fellowship! We’re so proud to have you join our family and can’t wait to work together to advance education, research, and patient care. @BCMHeart #BCMFellowship #Cardiology #FutureLeaders #ACCFIT – at Texas Medical Center, Houston
1
4
2
63
25,469
John M Suffredini retweeted
Patent foramen ovale (PFO) is present in approximately 25% of all adults and is a common cause of stroke in young and middle-aged patients. 📝 This Review discusses PFO-associated stroke management. ja.ma/430lxyZ
5
169
3
545
62,471
John M Suffredini retweeted
Sub-analysis of the BEST trial showing IVUS-guided PCI equivalent to CABG! An excellent review of the paper by @GreggWStone discussed how we can be better at what we do and be equivalent to bypass. In the order of importance, just in my opinion! 1-Intravscular imaging. A must, not an option. Needs meaningful use not just "use" 2-Complete revascularization- I am a huge believer. Complete the job 3-Physiology! will leave it to physiology enthusiasts :D heart.bmj.com/content/111/19… heart.bmj.com/content/111/19… #cardioX
6
51
1
150
14,072
John M Suffredini retweeted
Provocative study from the RENOVATE trialists and Samsung Med Cntr suggesting use of intravascular imaging may eliminate long-term diffs between CABG & PCI. Not definitive absent a powered RCT, but should be enough to mandate IVI in these pts, esp with class I guidelines. Agree?
12
64
5
216
28,771